Potential Therapeutic Benefit of Combining Gefitinib and Tamoxifen for Treating Advanced Lung Adenocarcinoma

Introduction. Epidermal growth factor receptor (EGFR) mutations are known as oncogene driver mutations and with EGFR mutations exhibit good response to the EGFR tyrosine kinase inhibitor Gefitinib. Some studies have shown that activation of estrogen and estrogen receptor α or β (ERα/β) promote adeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chien-Ming, Chiu, Kuo-Liang, Chen, Tzu-Sheng, Chang, Shang-Miao, Yang, Shu-Yun, Chen, Li-Hsiou, Ni, Yung-Lun, Sher, Yuh-Pyng, Yu, Sung-Liang, Ma, Wen-Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321093/
https://www.ncbi.nlm.nih.gov/pubmed/25692143
http://dx.doi.org/10.1155/2015/642041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4321093/
https://www.ncbi.nlm.nih.gov/pubmed/25692143
http://dx.doi.org/10.1155/2015/642041

Ejemplares similares